- Home
- GAME vs ACET Comparison
GAME vs ACET Comparison
Compare GAME & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- ACET
- Stock Information
- Founded
- GAME 2011
- ACET 1947
- Country
- GAME United States
- ACET United States
- Employees
- GAME N/A
- ACET N/A
- Industry
- GAME
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- ACET Health Care
- Exchange
- GAME Nasdaq
- ACET Nasdaq
- Market Cap
- GAME 70.2M
- ACET 63.5M
- IPO Year
- GAME 2009
- ACET N/A
- Fundamental
- Price
- GAME $0.74
- ACET $0.76
- Analyst Decision
- GAME Strong Buy
- ACET Buy
- Analyst Count
- GAME 2
- ACET 5
- Target Price
- GAME $3.00
- ACET $5.33
- AVG Volume (30 Days)
- GAME 2.6M
- ACET 463.1K
- Earning Date
- GAME 11-13-2025
- ACET 11-05-2025
- Dividend Yield
- GAME N/A
- ACET N/A
- EPS Growth
- GAME N/A
- ACET N/A
- EPS
- GAME N/A
- ACET N/A
- Revenue
- GAME $93,375,339.00
- ACET N/A
- Revenue This Year
- GAME $2.32
- ACET N/A
- Revenue Next Year
- GAME $26.42
- ACET N/A
- P/E Ratio
- GAME N/A
- ACET N/A
- Revenue Growth
- GAME 54.19
- ACET N/A
- 52 Week Low
- GAME $0.50
- ACET $0.45
- 52 Week High
- GAME $2.87
- ACET $1.57
- Technical
- Relative Strength Index (RSI)
- GAME 43.40
- ACET 51.10
- Support Level
- GAME $0.70
- ACET $0.77
- Resistance Level
- GAME $0.76
- ACET $0.84
- Average True Range (ATR)
- GAME 0.05
- ACET 0.06
- MACD
- GAME 0.01
- ACET 0.00
- Stochastic Oscillator
- GAME 49.52
- ACET 33.91
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.